Sidley Represents Crossbow Therapeutics in US$77 Million Series B Financing

Sidley represented Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, in its US$77 million Series B financing. The proceeds will support completion of the CROSSCHECK-001 Phase 1 clinical trial of the company’s lead program, CBX-250, and accelerate development of additional T-Bolt™ immunotherapies.

Crossbow is developing a broad portfolio of novel T-cell engager therapies that target peptide human leukocyte antigen on cancer cells using T-cell receptor mimetic antibodies. These investigational T-Bolt™ molecules are designed to address a wide range of malignancies and have the potential to expand the reach of antibody therapies across many cancer proteins.